BRPI0411843A - promotores rps21 e beta-actina e usos destes - Google Patents

promotores rps21 e beta-actina e usos destes

Info

Publication number
BRPI0411843A
BRPI0411843A BRPI0411843-0A BRPI0411843A BRPI0411843A BR PI0411843 A BRPI0411843 A BR PI0411843A BR PI0411843 A BRPI0411843 A BR PI0411843A BR PI0411843 A BRPI0411843 A BR PI0411843A
Authority
BR
Brazil
Prior art keywords
rps21
beta
actin promoters
promoters
hamster
Prior art date
Application number
BRPI0411843-0A
Other languages
English (en)
Inventor
Scott D Estes
Weiqun Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411843(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0411843A publication Critical patent/BRPI0411843A/pt
Publication of BRPI0411843B1 publication Critical patent/BRPI0411843B1/pt
Publication of BRPI0411843B8 publication Critical patent/BRPI0411843B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

"PROMOTORES RPS21 E BETA-ACTINA E USOS DESTES". A invenção refere-se ao isolamento de novos promotores de S21 (rpS21) de proteína ribossómica e usos destes. Em particular, esta invenção caracteriza seqüências de nucleotídeo para promotores de <225>-actina de roedor incluindo, hamster, rato e camundongo, e rpS21 de hamster.
BRPI0411843A 2003-06-24 2004-06-24 ácido nucleico compreendendo um promotor de beta-actina, vetor e método de produzir uma proteína BRPI0411843B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48076803P 2003-06-24 2003-06-24
PCT/US2004/017422 WO2005000888A2 (en) 2003-06-24 2004-06-24 NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF

Publications (3)

Publication Number Publication Date
BRPI0411843A true BRPI0411843A (pt) 2006-08-08
BRPI0411843B1 BRPI0411843B1 (pt) 2020-01-28
BRPI0411843B8 BRPI0411843B8 (pt) 2021-05-25

Family

ID=33551946

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411843A BRPI0411843B8 (pt) 2003-06-24 2004-06-24 ácido nucleico compreendendo um promotor de beta-actina, vetor e método de produzir uma proteína

Country Status (15)

Country Link
US (5) US7423135B2 (pt)
EP (3) EP2332972B1 (pt)
JP (2) JP4917886B2 (pt)
CN (5) CN101942442B (pt)
BR (1) BRPI0411843B8 (pt)
CA (1) CA2530020A1 (pt)
CY (1) CY1121580T1 (pt)
DK (2) DK2332972T3 (pt)
ES (2) ES2665493T3 (pt)
HU (2) HUE036449T2 (pt)
IL (3) IL172653A0 (pt)
PL (1) PL2332972T3 (pt)
PT (1) PT2332972T (pt)
SI (1) SI2332972T1 (pt)
WO (1) WO2005000888A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101942442B (zh) * 2003-06-24 2013-10-09 建新公司 新的β-肌动蛋白和RPS21启动子及其应用
WO2005010178A1 (ja) * 2003-07-29 2005-02-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 組換えフィブリノゲン高産生細胞の作製方法及び高産生細胞
US8298816B2 (en) * 2003-12-03 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter
PL2064337T3 (pl) * 2006-09-20 2012-12-31 Genzyme Corp Oparty na FACS i białku reporterowym układ do wysokowydajnego opracowywania białek terapeutycznych
CN102124019B (zh) * 2007-01-25 2017-09-15 惠觅宙 鸡β肌动蛋白基因内含子1的用途
WO2009155950A1 (en) * 2008-06-27 2009-12-30 King Faisal Specialist Hospital And Research Centre Cloning-free method of generating transcriptionally and post-transcriptionally controllable expression active linear reporter constructs
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
US20140186326A1 (en) 2011-04-22 2014-07-03 William Canfield Modified acid alpha glucosidase with accelerated processing
RU2014121383A (ru) * 2011-11-28 2016-01-27 Дайити Санкио Компани, Лимитед Происходящий из гена человека промотор
PT2844279T (pt) 2012-05-03 2021-03-11 Amicus Therapeutics Inc Esquema posológico para o tratamento da doença de pompe
WO2016172442A1 (en) * 2015-04-23 2016-10-27 Quest Diagnostics Investments Incorporated Mlh1 methylation assay
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
HUE056009T2 (hu) 2015-10-08 2022-01-28 Dna Twopointo Inc DNS vektorok, transzpozonok és transzpozázok eukarióta genom módosítására
CA3001238C (en) 2015-10-09 2024-06-25 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
CL2016001661A1 (es) 2016-06-29 2017-03-03 Univ Chile Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
EP3523440A1 (en) 2016-10-07 2019-08-14 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
CN109371106A (zh) * 2018-12-18 2019-02-22 湖南农业大学 赤眼鳟β-肌动蛋白基因cDNA全长序列、扩增引物及扩增方法
CN114269674A (zh) 2019-08-21 2022-04-01 因温特奥股份公司 扶手检查装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480768A (en) 1892-08-16 Paper-jogger
ES2273127T3 (es) * 1998-02-26 2007-05-01 Pioneer Hi-Bred International, Inc. Promotor alfa-tubulin 3-18 del maiz.
IL145545A0 (en) * 1999-04-06 2002-06-30 Univ California Human neurogenin 3-encoding nucleotide sequences
JP4119061B2 (ja) * 1999-10-18 2008-07-16 独立行政法人科学技術振興機構 眼皮膚白子症１ｂの原因遺伝子とその応用
JP4105523B2 (ja) * 2002-10-21 2008-06-25 独立行政法人科学技術振興機構 デルタ−サルコグリカン遺伝子の単独欠損ハムスター
CN101942442B (zh) * 2003-06-24 2013-10-09 建新公司 新的β-肌动蛋白和RPS21启动子及其应用
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements

Also Published As

Publication number Publication date
IL219838A0 (en) 2012-06-28
US8829176B2 (en) 2014-09-09
PT2332972T (pt) 2018-04-17
US20180155722A1 (en) 2018-06-07
DK1639112T3 (en) 2015-07-06
US20150040252A1 (en) 2015-02-05
EP1639112A2 (en) 2006-03-29
DK2332972T3 (en) 2018-04-23
US20080301826A1 (en) 2008-12-04
US9920318B2 (en) 2018-03-20
JP2011019525A (ja) 2011-02-03
EP1639112B1 (en) 2015-04-01
HUE025374T2 (hu) 2016-02-29
EP2332972A1 (en) 2011-06-15
EP3346010A1 (en) 2018-07-11
CN1813066A (zh) 2006-08-02
US7423135B2 (en) 2008-09-09
JP5646927B2 (ja) 2014-12-24
IL244477A0 (en) 2016-04-21
PL2332972T3 (pl) 2018-06-29
JP2007525956A (ja) 2007-09-13
CN107058313A (zh) 2017-08-18
CA2530020A1 (en) 2005-01-06
US10273479B2 (en) 2019-04-30
IL172653A0 (en) 2006-04-10
CY1121580T1 (el) 2020-07-31
CN101942442B (zh) 2013-10-09
BRPI0411843B8 (pt) 2021-05-25
EP2332972B1 (en) 2018-01-10
CN101942442A (zh) 2011-01-12
WO2005000888A2 (en) 2005-01-06
ES2665493T3 (es) 2018-04-26
CN1813066B (zh) 2010-04-28
IL219838A (en) 2016-09-29
CN103173447B (zh) 2016-12-21
IL244477B (en) 2019-05-30
US20050026252A1 (en) 2005-02-03
HUE036449T2 (hu) 2018-07-30
JP4917886B2 (ja) 2012-04-18
WO2005000888A3 (en) 2005-05-06
US20190300880A1 (en) 2019-10-03
CN101942443A (zh) 2011-01-12
CN103173447A (zh) 2013-06-26
BRPI0411843B1 (pt) 2020-01-28
ES2541136T3 (es) 2015-07-16
SI2332972T1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
BRPI0411843A (pt) promotores rps21 e beta-actina e usos destes
WO2005105829A3 (en) Caspase-2 inhibitors and their biological applications
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2004024757A3 (en) Modified pna molecules
WO2004072100A3 (en) Nell peptide expression systems and bone formation activity of nell peptide
DE60216798D1 (de) Azyklische linker enthaltende oligonukleotide und deren verwendungen
ECSP055584A (es) Proceso para la preparación de fibrinógeno
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2006132739A3 (en) Novel chemical compounds
BR0310115B1 (pt) processo para preparaÇço de dinitrilas de Ácido fenilmalânico.
WO2006119461A3 (en) Rat and mouse members of the crisp family of genes
HK1065054A1 (en) Process for the prepartion of thermoplastic, non-tacky polyurethanes
WO2005077397A3 (en) Methods and compositions for treating vascular diseases
WO2006127458A3 (en) Novel chemical compounds
DZ3174A1 (fr) Composition catalytique et procédé utilisant cettecomposition.
ATE533779T1 (de) Isoliertes photoprotein mtclytin, sowie dessen verwendung
WO2003066879A3 (en) Amino acid transporters
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
AU2003237493A1 (en) Methods for treating diseases or conditions with peptide constructs
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
WO2004016212A3 (en) Methods and compositions for targeting secretory lysosomes
WO2001053339A3 (en) Egg specific surface proteins
WO2004056762A3 (en) Novel aminobenzophenone compounds
WO2005060667A3 (en) Nucleic acid and amino acid sequences involved in pain

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 15/117 (2010.01), C12N 15/85 (2006.01), C12N

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF